Progress in Medicinal Chemistry – serie

Progress in Medicinal Chemistry provides a review of eclectic developments in medicinal chemistry. This volume continues in the serial's tradition of providing an insight into the skills required of the modern medicinal chemist; in particular, the use of an appropriate selection of the wide range of tools now available to solve key scientific problems.

Progress in Medicinal Chemistry provides a review of eclectic developments in medicinal chemistry. This volume continues in the serial's tradition of providing an insight into the skills required of the modern medicinal chemist; in particular, the use of an appropriate selection of the wide range of tools now available to solve key scientific problems.

Progress in Medicinal Chemistry, Volume 57, provides a review of eclectic developments in medicinal chemistry, with this volume including chapters on the CaSR field, CFTR modulators in cystic fibrosis, macrocycles, VMAT2 inhibitors, and Big Data in Drug Discovery.

Progress in Medicinal Chemistry, Volume 59, provides a review of eclectic developments in medicinal G139 chemistry. Each chapter is written by an international board of authors, with this release focusing on Small Molecules - Giant Leaps for Immuno-Oncology, Reviewing P2X7, Reviewing ASK1, and Reviewing DNA-encoded libraries.

This volume reviews recent advances in five important areas of medicinal chemistry which will be of interest both to chemists and to scientists of other disciplines engaged in medicines research and development. Included are accounts of successful drug discovery programmes, disease targets of unmet medical need, and recent progress in new technologies which are considered by many to hold the key to future developments in medicinal chemistry.The style and organisation of chapters follow a similar pattern to previous volumes but references, where appropriate, now include website addresses of the World Wide Web.

This volume covers contemporary advances in five important areas of pharmacology and medicinal chemistry including: a comprehensive account of inhibitors of the caspase family of proteolytic enzymes that represent a new class of anti-inflammatory and antiapoptotic agents of potential value in rheumatoid arthritis, and other peripheral and central indications; adoc umented survey of semi-synthetic and totally synthetic antibiotics and anti HIV agents and their sites of interaction; inhibitors of the intracellular enzyme acyl-CoA: cholesterol O-acyltransferase (ACAT) developed for the treatment of hypercholesterolemia; and recent progress in growth hormone secretagogues, with the focus on strategies to improve oral bioavailability and duration of action. Inhibition of the proteolytic enzyme, hepatitis C protease N-3(NS3), required for viral replication, is one of the most attractive targets for HCV infections. Progress and prospects in the design of peptide and non-peptide inhibitors are described here. design and clinical potential of new drug molecules; valuable summaries of structure-activity relationships in topical areas of medicinal chemistry; and extensive references to the biology, medicinal chemistry and clinical aspects of each topic.

This volume features accounts of the biological rationale, design and clinical potential of drug molecules; summaries of structure-activity relationships in topical areas of medicinal chemistry and extensive references to the biology, medicinal chemistry and clinical aspects of each topic.

This volume includes information on recent advances in five important areas: an account of inhibitors of the caspase family of proteolytic enzymes that represent a new class of anti-inflammatory and antiapoptotic agents of potential value in rheumatoid arthritis; and a survey of semi-synthetic and totally synthetic antibiotics and anti-HIV agents and their sites of interaction; the development of inhibitors of the intracellular enzyme acyl-CoA: cholesterol O-acyltransferase (ACAT) for the treatment of hypercholesterolemia; a description of recent progress in growth hormone secretagogues, with the focus on strategies to improve oral bioavailability and duration of action; and information on inhibition of the proteolytic enzyme, hepatitis C protease N-3(NS3), (required for vital replication) as one of the most attractive targets for HCV infections.

Progress in Medicinal Chemistry provides a review of eclectic developments in medicinal chemistry. This volume includes chapters covering recent advances in cancer therapeutics, fluorine in medicinal chemistry, a perspective on the next generation of antibacterial agents derived by manipulation of natural products, a new era for Chagas Disease drug discovery? and imaging in drug development.

Progress in Medicinal Chemistry provides a review of eclectic developments in medicinal chemistry. This volume includes chapters covering recent advances in cancer therapeutics, fluorine in medicinal chemistry, a perspective on the next generation of antibacterial agents derived by manipulation of natural products, a new era for Chagas Disease drug discovery? and imaging in drug development.

Progress in Medicinal Chemistry, Volume 56 provides a review of eclectic developments in medicinal chemistry. This volume includes chapters covering recent advances in cancer therapeutics, fluorine in medicinal chemistry, a perspective on the next generation of antibacterial agents derived by manipulation of natural products, a potential new era for Chagas Disease drug discovery, and imaging in drug development. Specific chapters cover timely topics, such as the development of LRRK2 inhibitors for the treatment of Parkinson's, and recent discoveries and developments in TRPA1 modulators.

Users will find a comprehensive resource on the topic of medicinal chemistry that also discusses avenues for the acceleration of drug discovery programs.

Progress in Medicinal Chemistry, Volume 58, provides a review of eclectic developments in medicinal chemistry, with each chapter written by an international board of authors. Topics covered in this new release include Amyotrophic lateral sclerosis (ALS), Covalent-binding Drugs, Natural Product Drug Delivery - A Special Challenge?, and SMN2 gene splicing modifier, and more.

There are five main subject areas in this volume in the series on medicinal chemistry. The first is a review of the understanding of Alzheimer's disease and the development of drugs for its treatment; the second, looking at recent efforts in modifying a naturally occuring anticancer (campothecin) for chemotherapy; the third covers the problem of getting a drug to a specific site within the context of phosphates and phosphonates; a survey of sterilization using aldehydes for the destruction of microbes both inside and outside the human body is reviewed in the fourth; and the last chapter is an account of the progress made in the biologically active enantiomer for complex synthetic asymmetric drug molecules.